Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

Zeneca describes ET antagonists

Feb. 14, 1997

ICOS' Hu23F2G enters phase II

Feb. 13, 1997

Novel antiarrhythmic agents described by Merck & Co.

Feb. 13, 1997

Novartis launches once-daily hypertension Rx

Feb. 12, 1997

Alexion receives grant for complement inhibitors

Feb. 12, 1997

Sulfonamide derivatives for inhibition of cell adhesion

Feb. 12, 1997

American Home Products describes antiproliferative agents

Feb. 12, 1997

T Cell Sciences awarded second grant for vaccine development

Feb. 11, 1997

ET antagonists reported by Japanese investigators

Feb. 11, 1997

German researchers focus on Na+/H+-exchange inhibitors

Feb. 10, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...